CC
TRVI icon

Centiva Capital’s Trevi Therapeutics TRVI Stock Holding History

Centiva Capital’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,048
Closed -$41.4K – 2139
2024
Q4 		$41.4K Buy
+10,048
New +$32.2K ﹤0.01% 1551

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Centiva Capital's TRVI Position: Q1 2025 in Review

Centiva Capital sold out of Trevi Therapeutics (TRVI) in Q1 2025, closing a stake of 10,048 shares — an estimated $41.4K sold.

Centiva Capital first reported a position in TRVI in Q4 2024 and held it in 1 quarter. The position peaked at $41.4K in Q4 2024. 137 funds tracked by Wall St. Rank hold TRVI as of Q1 2025.

  • Centiva Capital reported no remaining Trevi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Centiva Capital sold 10,048 Trevi Therapeutics shares in Q1 2025, an estimated $41.4K.
  • Centiva Capital first reported a position in Trevi Therapeutics in Q4 2024 and held it in 1 quarter.
  • Centiva Capital's Trevi Therapeutics position peaked at $41.4K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.